Development and validation of a mortality risk prediction model for chronic obstructive pulmonary disease: a cross-sectional study using probabilistic graphical modelling
This research was supported by NIH [NHLBI, NLM]. The COPDGene study is supported by the COPD Foundation, through grants from AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer and Sunovion.
Authors
- Minxue Jia (ORCID: https://orcid.org/0000-0001-9305-1218)
- Frank C. Sciurba (ORCID: https://orcid.org/0000-0001-7468-2225)
- Panayiotis V. Benos (ORCID: https://orcid.org/0000-0003-3172-3132)
- Min Hyung Ryu (ORCID: https://orcid.org/0000-0003-3071-7363)
- Peter J. Castaldi (ORCID: https://orcid.org/0000-0001-9920-4713)
- Craig P. Hersh (ORCID: https://orcid.org/0000-0002-1342-4334)
- Tyler Lovelace (ORCID: https://orcid.org/0000-0002-7881-9054)
Institutions
- Brigham and Women's Hospital (US)
- University of Pittsburgh (US)
- University of Florida (US)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.eclinm.2024.102786
- Citations
- 6
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- University of Florida
- COPD Foundation
- Sunovion
- National Institutes of Health
- Genentech
- National Heart, Lung, and Blood Institute